Clinical trials
catalyst calendar across sponsors →Studies where BDTX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional · 1 with posted results
Held by 7 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, MARSHALL WACE, LLP, Balyasny Asset Management L.P., JANE STREET GROUP, LLC, D. E. Shaw & Co., Inc., +2 more) · FINRA short interest 8.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIINCT07326566Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR)Randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: silevertinib in combination with temozolomide, temozolomide (TMZ) | Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM), Glioma, Central Nervous System Diseases, Brain Cancer | 162 | Nov 2028 | ≤ 834 d | 2026-08-13 |
| Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR MutationsNCT05256290Phase 1 Dose Escalation: To determine the maximum tolerated dose (MTD), if one exists, and the preliminary recommended Phase 2 dose(s) (RP2D[s]) of silevertinib (BDTX-1535)Non-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: silevertinib (BDTX-1535) monotherapy | Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation | 200 | 2025-11-03actual | — | 2026-07-22 |
| A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.NCT04209465results2025-04-17Number of Dose Limiting Toxicities as a Determinant of the Recommended Phase 2 Dose (RP2D)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: The development of BDTX-189 was discontinued by the sponsor. | Drug: BDTX-189 | Solid Tumor | 91 | 2022-09-02actual | — | 2025-04-17 |
| Identification of a Safe and Non-Psychedelic Dose of PsilocybinNCT07710027Clinical Safety Event FrequencyRandomized · Quadruple-masked · Basic science | Phase 1 | Completed | Drug: Psilocybin (low dose) or Placebo | Healthy Controls | 56 | 2022-03-12actual | — | 2026-07-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19